What we’re about
Welcome to the newest virtual home of the Philadelphia Area Java Users’ Group, twice rated by Sun as one of the world’s top Java User Groups! The Philly JUG’s main objective is to provide great learning events for our membership, and if you look at our history we’ve done just that. Over the past fifteen+ years the Philly JUG has done quite a bit of growing up. Very few of you might remember our first meeting, where about 35 members sat on the floor in the office of a long departed dot com. If you have been to a meeting recently you know how far we have come.
Current Philly JugMaster: Jason Young.
Upcoming events (2)
See all- Lightning (Fast Startups) in the JarCertara, Radnor, PA
Project Leyden is coming! Since the rise in popularity of microservice architectures in the mid-2010s, and serverless a few years later, the importance of startup and time to peak performance have become metrics of increasing concerns in the software development world.
The JVM is fast, incredibly fast, with throughput comparing favorably to even natively-compiled languages like C++ and Rust. However the JVM is a VM, which means it has historically lagged behind in startup and warm up.
That is what Project Leyden, an OpenJDK project, is seeking to change. In this presentation we will look at the goals and features that are coming with Project Leyden, and how they will help improve startup and time to peak performance on the JVM.
About the Speaker
Billy Korando
Billy is a Java Developer Advocate with the Java Platform Group at Oracle. With over a decade of experience in Java, Billy brings a passion for helping developers reduce tedious work, such as project initiation, deployment, testing, and validation, through automation and adopting the latest features and tools in the Java ecosystem. Outside of work, Billy enjoys traveling, playing kickball, and cheering on the Kansas City Chiefs. Billy also co-organizes the Kansas City Java users group.About the Sponsor
Certara (https://www.certara.com)
Certara accelerates medicines to patients, using biosimulation (modeling and simulation) and technology-enabled services to transform drug discovery and development. Our integrated and proprietary end-to-end platform with generative AI technology, biosimulation, regulatory science, and market access solutions combined with our global 1,400+ strong team of scientists and experts enable informed decision-making, higher R&D productivity, and improved patient outcomes.
